FDA
-
-
-
-
-
-
-
Dr. Reddys Labs (RDY) Launches Treprostinil Injection in the U.S.
-
-
-
-
-
-
-
Eton Pharmaceuticals (ETON) Announces Sale of Hospital Products to Dr. Reddy’s (RDY) for Up to $50M
-
-
-
-
-
-
-
Dr. Reddy's Laboratories Announces the Launch of Posaconazole Delayed-Release Tablets in the U.S. Market
-
-
-
-
-
-
-
Prestige BioPharma and Dr. Reddy’s announce partnership to commercialize trastuzumab biosimilar in select countries in Latin America and Southeast Asia
-
-
-
-
-
-
-
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
-
-
-
-
-
-
-
Dr. Reddys Labs (RDY) Sells its U.S. and Canada Territory Rights for ELYXYB to BioDelivery Sciences
-
-
-
-
-
-
-
Dr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market
-
251,370 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All